Category — Pharmaceuticals

India’s Aurobindo Pharma to Expand New Jersey Facility

At its current New Jersey facility,  the company makes non-penicillin and non-cephalosporin products. The bulk of its U.S. supply comes from India, where it has six plants. It gets more than half its total revenue from selling drugs for HIV/AIDS, asthma, and schizophrenia, among others, to the U.S.

India’s drug industry is worth about $15 billion and it supplies roughly 30 percent of the medicines sold in the U.S. reports Business Line.

June 11, 2017   No Comments

Jubilant Pharma Expected to Buy American Pharma Company

Noida, India-based Jubilant Life Sciences‘ subsidiary Jubilant Pharma will negotiate a potential acquisition of a specialty business in the U.S., subject to due diligence, satisfactory agreements, and final approval of Jubilant Life Sciences.

A vial of medicine for injection

 

BusinessLine reports on a company filing at the Bombay Stock Exchange that says, “the proposed acquisition is a niche, profitable specialty pharma business with a strategic fit and is expected to provide a competitive edge for Jubilant Life Sciences’ existing business, if it materializes.”

June 11, 2017   No Comments

India Launches National Pharma Mission

The Government of India launched the National Pharma Mission for the development of bio pharmaceuticals through industry-academia collaboration. This program will focus on the development of specific products such as vaccines, biotherapeutics, and newer platform technologies for medical devices and diagnostics.

Funded by India’s central government and through a loan from the World Bank, the Mission will be implemented by the Biotechnology Industry Research Assistance Council (BIRAC), a unit of the  Department of Biotechnology. Renu Swarup, managing director of BIRAC said, “This mission is not for new discovery, but for creating infrastructure to move important early leads, which are in different stages, through the pipeline, and create products.”

Research

The National Biotechnology Development Strategy 2015-2020 announced by the Department of Biotechnology lays emphasis on making India ready to meet the challenge of achieving a $100 billion biotech industry by 2025, reports the Indian Express.

June 8, 2017   No Comments

Corning Life Sciences Bullish on India

In an interview with the Economic Times’ Healthworld, Dr. Richard M. Eglen, vice president and general manager of Corning Life Sciences, discussed the company’s business growth in India.

On Corning Life Science’s business in India

Eglen: India is one of our fastest growing markets in the Asia Pacific region. As a market, India has shown great potential and continues to grow significantly and drive growth for Corning Life Sciences outside of the U.S. With India’s population slated to reach 1.4 billion by 2022 (per the 2015 UN Report on World Population), this growing population demands not only large-scale production of vaccines, but also research for newer vaccines relevant to India.
Corning’s bioprocess products provide a full range of tools to successfully perform vaccine scale-up and production. Our cell culture products are of great interest to Indian pharmaceutical companies.

Corning's Cell Culture Tools

On Corning’s India’s revenue share

Eglen: The total sale of Asia represents over 50% of Corning’s total sales of US $ 9.1 billion worldwide in 2015. We can also tell you that we have more than doubled our revenues in India since 2009. 2015 was our strongest performance in Corning Life Science India history and we have kept the momentum going in 2016.

On future plans for the Indian market

Eglen: The Indian pharmaceutical market is currently at $25 billion and is expected to continue to grow at a CAGR of 12% till 2020. India is 3rd largest pharmaceutical market in the world by incremental growth and 7th largest by volume which gives Corning Life Sciences an immense growth opportunity. We have opened a warehouse for life sciences products for Indian customers in Mumbai which shows our commitment to be a reliable supplier for our customers in India.

 

December 29, 2016   No Comments

India’s Pharma Industry Becoming Increasingly Digital

The Economic Times reports that in a survey of drug making companies in India’s $17 billion pharmaceutical industry the top 20 of them are changing their conservative ways of marketing for newer technology ranging from scientific detailing to doctors to using newer algorithms for better insights into issues like patient compliance.

Digital heartbeat

Mobile apps and social media will play a bigger role in this growth, the study that is part of a larger report on global digital marketing trends found. Marketing spends through digital platforms is estimated to shoot up nearly 50% in the next two years to touch $33 million, Bangalore-based market research firm Indegene‘s study shows.

Sun Pharma launched a mobile app called RespiTrack earlier this year to ensure patients with asthma adhere to treatment regimens; GlaxoSmithKline’s local unit says that at least 20%-30% of its customers are already in the digital world; and Abbott Healthcare has introduced several tools like Knowledge Genie, a heart and liver app, and another one for vertigo exercises. Some of these build on augmented and virtual reality to engage with both doctors and patients.

 

 

November 15, 2016   No Comments